SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009; 6: 63847.
  • 2
    Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review [review] [published erratum appears in Arthritis Rheum 2010;62:2555]. Arthritis Rheum 2010; 62: 921.
  • 3
    Coggins PR, Ravdin RG, Eisman SH. Clinical pharmacology and preliminary evaluation of Cytoxan (cyclophosphamide). Cancer Chemother Rep 1959; 3: 911.
  • 4
    Goldman RL, Warner NE. Hemorrhagic cystitis and cytomegalic inclusions in the bladder associated with cyclophosphamide therapy. Cancer 1970; 25: 711.
  • 5
    Rubin JS, Rubin RT. Cyclophosphamide hemorrhagic cystitis. J Urol 1966; 96: 3136.
  • 6
    Cyclophosphamide and the bladder. Br Med J 1971; 2: 7267.
  • 7
    Worth PH. Cyclophosphamide and the bladder [letter]. Br Med J 1971; 3: 182.
  • 8
    Fairchild WV, Spence CR, Solomon HD, Gangai MP. The incidence of bladder cancer after cyclophosphamide therapy. J Urol 1979; 122: 1634.
  • 9
    Levine E. Transitional cell carcinoma of the renal pelvis associated with cyclophosphamide therapy. AJR Am J Roentgenol 1992; 159: 10278.
  • 10
    McDougal WS, Cramer SF, Miller R. Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease. Cancer 1981; 48: 6915.
  • 11
    Pedersen-Bjergaard J, Ersboll J, Hansen VL, Sorensen BL, Christoffersen K, Hou-Jensen K, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988; 318: 102832.
  • 12
    Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87: 52430.
  • 13
    Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 7685.
  • 14
    Stillwell TJ, Benson RC Jr, DeRemee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988; 31: 46570.
  • 15
    Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 1971; 285: 14936.
  • 16
    Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 1971; 284: 93842.
  • 17
    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 48898.
  • 18
    Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 47784.
  • 19
    Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9: 84252.
  • 20
    Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 102132.
  • 21
    Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004; 63: 130711.
  • 22
    Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35: 1005.
  • 23
    De Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16: 201827.
  • 24
    Guillevin L, Jarrousse B, Lok C, Lhote F, Jais JP, Le Thi Huong Du D, et al, the Cooperative Study Group for Polyarteritis Nodosa. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange: a prospective randomized trial of 71 patients. J Rheumatol 1991; 18: 56774.
  • 25
    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 18792.
  • 26
    Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 434.
  • 27
    French Institute for Public Health Surveillance. Estimation de l'incidence et de la mortalité par cancer en France de 1978 à 2000. URL: http://www.invs.sante.fr/surveillance/cancers/estimations_cancers/donnees_localisation/vessie/default.htm.
  • 28
    Sun J, Ono Y, Takeuchi Y. A simple method for calculating the exact confidence interval of the SMR with a SAS function. J Occup Health 1996; 38: 19697.
  • 29
    Guillevin L, Fain O, Lhote F, Jarrousse B, Le Thi Huong D, Bussel A, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome: a prospective, randomized trial in 78 patients. Arthritis Rheum 1992; 35: 20815.
  • 30
    Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges: a prospective trial in 33 patients. J Rheumatol 1993; 20: 28998.
  • 31
    Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Genereau T, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: a prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 163845.
  • 32
    Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, et al, the French Cooperative Study Group for Vasculitides. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. Br J Rheumatol 1997; 36: 12907.
  • 33
    Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 218798.
  • 34
    Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, et al, and the French Vasculitis Study Group. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003; 49: 93100.
  • 35
    Guillevin L, Mahr A, Cohen P, Larroche C, Queyrel V, Loustaud-Ratti V, et al, for the French Vasculitis Study Group. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus–related polyarteritis nodosa. Arthritis Rheum 2004; 51: 4827.
  • 36
    Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, Le Guern V, et al, for the French Vasculitis Study Group. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007; 57: 68693.
  • 37
    Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al, for the French Vasculitis Study Group. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008; 58: 30817.
  • 38
    Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Lauque D, et al, for the French Vasculitis Study Group. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008; 58: 58694.
  • 39
    Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790803.
  • 40
    De Menthon M, Cohen P, Pagnoux C, Sibilia J, Jaussaud R, Delaval P, et al. Infliximab versus rituximab for refractory Wegener's granulomatosis: a prospective, randomized, multicenter study on 21 patients [abstract]. APMIS 2009; 117 Suppl: S72.
  • 41
    Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Puechal X, et al, for the French Vasculitis Study Group. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 2010; 62: 118697.
  • 42
    Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al, for the European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody–associated vasculitis: a randomized controlled trial. JAMA 2010; 304: 23818.
  • 43
    Cohen SM, Garland EM, St John M, Okamura T, Smith RA. Acrolein initiates rat urinary bladder carcinogenesis. Cancer Res 1992; 52: 357781.
  • 44
    Batista CK, Brito GA, Souza ML, Leitao BT, Cunha FQ, Ribeiro RA. A model of hemorrhagic cystitis induced with acrolein in mice. Braz J Med Biol Res 2006; 39: 147581.
  • 45
    Cox PJ. Cyclophosphamide cystitis—identification of acrolein as the causative agent. Biochem Pharmacol 1979; 28: 20459.
  • 46
    Hows JM, Mehta A, Ward L, Woods K, Perez R, Gordon MY, et al. Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. Br J Cancer 1984; 50: 7536.
  • 47
    Shepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips GL. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991; 9: 201620.
  • 48
    West NJ. Prevention and treatment of hemorrhagic cystitis. Pharmacotherapy 1997; 17: 696706.
  • 49
    Habs MR, Schmahl D. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2′-dithio-bis-ethane sulfonate (dimesna). Cancer 1983; 51: 6069.
  • 50
    Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies and cyclophosphamide exposure in Wegener's granulomatosis. J Rheumatol 2008; 35: 113.
  • 51
    Zeegers MP, Tan FE, Dorant E, van den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000; 89: 6309.
  • 52
    ParkinDM WhelanSL FerlayJ TeppoL ThomasDB, editors. Cancer incidence in five continents, vol. VIII. IARC scientific publication 155. Lyon (France): International Agency for Research on Cancer (WHO); 2002. URL: http://www.iarc.fr/en/publications/pdfs-online/epi/sp155/index.php.